✦ LIBER ✦

Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG (S0200) phase 3 randomized trial

✍ Scribed by Maurie Markman; James Moon; Sharon Wilczynski; Ana Maria Lopez; Kendrith M. Rowland Jr.; David P. Michelin; Victor J. Lanzotti; Garnet L. Anderson; David S. Alberts

Book ID: 113962338
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 218 KB
Volume: 116
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2009.11.026

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Final overall survival results of phase

Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients

✍ Wagner, U; Marth, C; Largillier, R; Kaern, J; Brown, C; Heywood, M; Bonaventura, 📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 242 KB

A randomized phase II study of carboplat

A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study

✍ Dimitrios Bafaloukos; Helena Linardou; Gerasimos Aravantinos; Christos Papadimit 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 332 KB

Randomized trial of pegylated liposomal

Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200)

✍ David S. Alberts; P.Y. Liu; Sharon P. Wilczynski; Mary C. Clouser; Ana Maria Lop 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 163 KB

Carboplatin and pegylated liposomal doxo

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial

✍ Gladieff, L.; Ferrero, A.; De Rauglaudre, G.; Brown, C.; Vasey, P.; Reinthaller, 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 124 KB

A phase II clinical trial of pegylated l

A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer

✍ Marcela G. del Carmen; John Micha; Laurie Small; Daron G. Street; Anil Londhe; T 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 254 KB

Safety of a 3-weekly schedule of carbopl

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

✍ Sandro Pignata; Giovanni Scambia; Antonella Savarese; Enrico Breda; Paolo Scollo 📂 Article 📅 2006 🏛 BioMed Central 🌐 English ⚖ 247 KB